Skip to content

Nissen Versus Dor Hiatal Hernia Repair

NiDor-study: a Randomized Controlled Trial Comparing Nissen and Dor Fundoplication in Hiatal Hernia Repair

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06725433
Acronym
NiDor
Enrollment
150
Registered
2024-12-10
Start date
2025-02-07
Completion date
2030-01-30
Last updated
2025-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hiatal Hernia, Paraesophageal Hernia, Recurrence

Brief summary

Hiatal hernia can present with a wide range of symptoms. An usual surgical repair technique usually includes Nissen fundoplication, while other procedures are less frequently employed. However, recurrence and reoperation rates remain high. This randomized controlled trial aims to compare the efficacy of Nissen and Dor fundoplication in preventing hiatal hernia recurrence and reducing the risk of reoperation Participants undergoing minimally invasive hiatal hernia repair will be randomly assigned to either Nissen or Dor fundoplication. Postoperatively at 12 months, anatomical recurrence rates based on computed tomography scans and symptomatic recurrence rates, anti-reflux medication use, GERD-related quality of life, and dysphagia symptoms will be assessed. A subsequent long-term follow-up study will conducted afterwards utilizing national registry data to evaluate reoperation rates and anti-reflux medication use

Interventions

Hiatal hernia repair and Nissen fundoplication

Hiatal hernia repair and Dor fundoplication

Sponsors

Kuopio University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Prospective open label randomized trial

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 18 years of age * Type II-IV hiatal hernia, confirmed by radiology or endoscopy * Scheduled for mini-invasive hiatal hernia repair * Emergency mini-invasive surgery for hiatal hernia * The informed consent is acquired

Exclusion criteria

* Recurrent hiatal hernia * Need for esophageal lengthening procedure (Collis) * Gangrene or need for any resection during (emergency) surgery * Need for laparotomy or thoracotomy/thoracoscopy * No written consent

Design outcomes

Primary

MeasureTime frameDescription
Anatomical recurrence of hiatal hernia12 months after the surgeryComputed tomography based recurrence after Nissen versus Dor fundoplication
Symptomatic recurrence of hiatal hernia12 months after the surgeryAnatomical recurrence with questionnaire based gastroesophageal reflux disease (GERD) or dysphagia symptoms, or need for reoperation for recurrence

Secondary

MeasureTime frameDescription
Managing GERD symptoms with Nissen vs Dor fundoplication12 monthsThe efficacy of Nissen vs Dor fundoplication techniques in improving the Gastroesophageal Reflux Disease-Health Related Quality of Life instrument (GERD-HRQL) scores at 12 months. Minimum score 0 = no symptoms, maximum score 75 = worst symptoms.
Dysphagia symptoms after Nissen vs Dor fundoplication12 monthsThe effect of different fundoplication techniques on dysphagia symptoms assessed by Eating Assessment Tool (EAT-10 ) at 12 months. Score range from 0 to 40 with higher scores indicating more severe dysphagia.
Hiatal hernia size and recurrence rates12 monthsThe association between hiatal hernia size and recurrence rates. During surgery, the left-to-right and posterior-to-anterior dimensions of the hiatal opening, as well as whether more than 30% of stomach is herniated , will be recorded. These measurements will then be compared to postoperative recurrence rates.
Symptomatic versus asymptomatic recurrence rates12 monthsSymptomatic versus asymptomatic recurrence rates at 12 months
The impact of Body Mass Index on recurrence and reoperation rates20 yearsThe impact of initial Body Mass Index (BMI, kg/m\^2) on the recurrence rates (12 months) and reoperation rates (1-, 3-, 5-, 10- and 20-years)
The impact of age on recurrence and reoperation rates20 yearsThe impact of subject age (years) on the recurrence rates (12 months) and reoperation rates (1-, 3-, 5-, 10- and 20-years)
The impact of albumin level on recurrence and reoperation rates20 yearsThe impact of albumin level (g/l) on the recurrence rates (12 months) and reoperation rates (1-, 3-, 5-, 10- and 20-years)
Proton pump inhibitor usage20 yearsProton pump inhibitor usage will be assessed at 1- 3-, 5-, 10- and 20-years after surgery
Reoperation rates20 yearsReoperation rates at 3-, 5-, 10- and 20-years following the surgery

Countries

Finland

Contacts

Primary ContactVille Palomäki, MD, PhD
Ville.Palomaki@pshyvinvointialue.fi+35817 173 311

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026